Bio Product Guide

Study Shows Some Antibodies Attack Cytokines

Jim Marino — Tue, 02 Feb 2010 05:58:23 +0000

Two studies published on February 1 in the Journal of Experimental Medicine reveal that patients with a rare autoimmune disease produce antibodies that attack microbe-fighting immune proteins called cytokines. These findings may help in explaining the reasons of some patients catching yeast infections recurrently. Autoimmune polyendocrine syndrome, or APS-I, afflicts one in 100,000 people and is characterized by disrupted thyroid and adrenal gland function and recurrent skin infections with one type of yeast.

Llamas can help fight bio-terrorism: Scientists

Jim Marino — Mon, 25 Jan 2010 06:44:42 +0000

Scientists at Foundation for Biomedical Research (SFBR) in Texas claimed to have developed the BoNT-detecting substances or the antibodies – proteins made by the body to fight diseases – found in llamas. The llama antibodies, called single domain antibodies (sdAb) are molecularly flexible, unlike conventional antibodies, ScienceDaily reported. BoNTs directly hit the nervous system, resulting in paralysis that can be so severe as to require life support on a mechanical ventilator for weeks to months.

For the full story, Click Here

NAMPA: FDA Reaffirms That Current Uses Of BPA Pose No Risk; Calls For More BPA Research

Jim Marino — Mon, 18 Jan 2010 15:37:54 +0000

The North American Metal Packaging Alliance, Inc. (NAMPA) supports the U.S. Food and Drug Administration’s (FDA) announcement today to continue its ongoing scientific research and evaluation of bisphenol A (BPA). At the same time, FDA officials reiterated that consumers can continue to use safely existing products that contain BPA. The FDA announcement clearly noted that BPA exposure is not proven to harm children or adults which is consistent with other international regulatory bodies.

For the full story, Click Here

FDA Approves ACTEMRA(R) (tocilizumab) For The Treatment Of Moderately To Severely Active Rheumatoid Arthritis

Jim Marino — Tue, 12 Jan 2010 06:19:46 +0000

Genentech, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. ACTEMRA is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat RA, and may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs.

For the full story, Click Here

FDA Approves Cymbalta(R) For Maintenance Treatment Of Generalized Anxiety Disorder

Jim Marino — Mon, 04 Jan 2010 10:55:50 +0000

The U.S. Food and Drug Administration has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, Eli Lilly and Company announced. The efficacy and safety of Cymbalta for the maintenance treatment of GAD were established in a double-blind, placebo-controlled trial. Patients with GAD who initially had responded to treatment with Cymbalta 60-120 mg/day during a 26-week open-label phase were randomly assigned to receive Cymbalta 60-120mg/day or placebo.

For the full story, Click Here

AnaSpec Adds Z-Fish(TM) MMP Antibodies to MMP Research Portfolio

Jim Marino — Mon, 28 Dec 2009 07:07:50 +0000

AnaSpec has introduced the industry’s most comprehensive collection of anti-MMP zebrafish (Z-Fish(TM)) specific antibodies. AnaSpec’s existing portfolio of MMP research products includes SensoLyte(R) MMP assay kits, GO(TM) (catalog) MMP peptides, and MMP recombinant proteins products. The new MMP products include a wide selection of Z-Fish(TM) as well as human-specific MMP antibodies. Matrix metalloproteinases (MMPs) are members of a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling.

For the full story, Click Here

PDL BioPharma Announces New Licensing Agreement With Eli Lilly

Jim Marino — Tue, 22 Dec 2009 09:42:27 +0000

PDL BioPharma, Inc. has announced that it has entered into a non-exclusive license agreement with Eli Lilly and Company under PDL’s Queen et al patents with respect to teplizumab, a humanized anti-CD3 monoclonal antibody, as well as other potential next generation anti-CD3 molecules. Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus. No other details of the licensing agreement were made available.

For the full story, Click Here

New research centers on link between nutrition and brain function

Jim Marino — Tue, 15 Dec 2009 11:18:10 +0000

A study published in the Archives of Internal Medicine divided a group of 106 overweight and obese people into two groups: About half spent a year following a diet low in fat – say goodbye to steak and pastries – and high in carbohydrates. The other half went for a year on a low-carb, high-fat diet – have a burger, but skip the bun. In both groups, people lost an average of 30 pounds each.

For the full story, click here

Adrima Corporation announces new antioxidant supplement which utilizes beneficial microbes

Jim Marino — Tue, 08 Dec 2009 15:22:37 +0000

The Adrima Corporation has announced that they will be offering a new antioxidant supplement that utilizes Effective Microorganisms™. This is an innovative green technology which is beneficial for humans, animals, and plants. With healthcare costs at an all time high, the company has stated that their product is an effective way to take preventative action and help avoid unnecessary and costly medical problems in the future.

Arthritis connected with childhood physical abuse say researchers

Jim Marino — Tue, 01 Dec 2009 13:02:34 +0000

A study from University of Toronto claims that adults who underwent physical abuse as children have about 56 per cent more chances of suffering from osteoarthritis as opposed to those who have not been abused. Osteoarthritis is said to occasionally be an incapacitating severe condition that affects millions of adults. The experts examined the affiliation between self-reported childhood physical abuse and detection of osteoarthritis (OA).